Oncogenic PTC/RET translocations detected in thyroid cancer and cell lines are sensitive in vitro and in vivo to RET inhibitors [16–19], suggested the possibility that sunitinib, sorafinib, vandetanib, or other RET inhibitors might also be clinically effective in KIF5B/RET lung cancers. Here, RET is linked to thyroid cancer.